FINWIRES · TerminalLIVE
FINWIRES

Brookfield's Valuation Remains Disconnected From Fundamentals, RBC Says

By

Brookfield (BN) shares are trading at a 40% discount to management's estimate of current plan value and a 50% discount to RBC's forward net asset value estimate, leaving valuation disconnected from fundamentals and making the stock a top pick, RBC Capital Markets said Friday.

The brokerage said Brookfield targeting a 24% compound annual growth rate for distributable earnings with Wealth Solutions is a key contributor to growth. The company is targeting a 17% CAGR in distributable earnings per share from 2026 to 2031 from its base business, largely in-line with last year's growth targets, according to the note.

Management highlighted its expectation of $25 billion realized carried interest over the next 10 years, with $11 billion expected over the next 5 years, the note added.

Despite monetization increasing 3 times from $30 billion in 2021 to nearly $90 billion in 2026, the $5 billion targeted over the next 1 to 3 years is 17% lower than the $6 billion outlook provided at last year's investor day, the brokerage said.

While RBC expects higher rates to impact real estate in the near-term, with real estate accounting for about 18% of Brookfield's NAV, longer-term outlook remains constructive due to improving demand and supply fundamentals in both office and retail real estate markets, as well as the company's progress on its monetization plan, the brokerage added.

RBC kept an outperform rating on Brookfield with a price target of $61.

Price: $37.16, Change: $-0.03, Percent Change: -0.09%

What else is happening in Wire?

Wire

Loop Industries to Evaluate Alternatives, India Joint Venture Financing

Loop Industries (LOOP) formed a committee to evaluate alternatives aimed at advancing commercialization and strengthening its capital position, including a broader project-financing structure for its planned India joint venture.The review will consider "strategic investments, project-level financing, licensing and commercial partnerships, regional joint ventures, business combinations, corporate-structure alternatives, a potential sale, merger or going-private transaction," the company said Thursday in a statement.Loop said there is no assurance the process will result in a sale, merger, going-private transaction or any other transaction or outcome.The review follows Jeff Geygan's appointment as chairman and the separation of the chairman and CEO roles, establishing a board-led process to evaluate capital needs and strategy.Loop shares rose 2% in after-hours trading.

$LOOP
Wire

Top Cryptocurrencies Rise; Bitcoin Tops $76,000 Level

Major digital assets rose Thursday, with Bitcoin (BTC-USD) topping the $76,000 level.The CoinDesk Market Index, which tracks dozens of digital assets including Bitcoin, rose 2% in the past 24 hours. The Nasdaq 100 rose 1.8%, the S&P 500 added 1.2%, and the Dow Jones Industrial Average increased 0.6%.Bitcoin gained 0.8% to $76,473, according to CoinMarketCap data. The most popular cryptocurrency's 24-hour trading volume dropped 24.4% to $23.4 billion.Ethereum (ETH-USD), the second-largest digital asset by market value, rose 1.8% to $2,445.XRP (XRP-USD) declined 0.3%, BNB (BNB-USD) rose 1.6%, and Solana (SOL-USD) gained 2.6%. Dogecoin (DOGE-USD) increased 1.5%, while Cardano (ADA-USD) advanced 3.7%.The total market value of the cryptocurrency industry rose 1.2% in the past 24 hours to $2.62 trillion, with trading volume dropping 12.6% to $77 billion.Price: $76600.00, Change: $+456.19, Percent Change: +0.60%

$ADA-USD$BNB-USD$BTC-USD$DOGE-USD$ETH-USD$SOL-USD$XRP-USD
Wire

Ultragenyx Shares Rise After FDA Approval for Sanfilippo Syndrome Treatment

Ultragenyx Pharmaceutical (RARE) shares rose 11% after the company won FDA approval for Fayuvi, the first treatment for children with Sanfilippo syndrome type A, a rare genetic condition that progressively damages the brain and nervous system.Delivered as a one-time IV infusion, Fayuvi uses a modified virus to deliver a healthy gene, replacing the enzyme the patients lack. the FDA said Thursday in a statement. In clinical trials, treated children aged 2 to 5 maintained or improved their cognitive abilities compared to historical patient outcomes, the agency said.The FDA noted common side effects like fever, nausea, and elevated liver enzymes. The label also warns of potential long-term risks, including blood clotting issues and tumor formation, requiring patients to take immune-suppressing steroids around the time of treatment.Price: $14.34, Change: $+1.46, Percent Change: +11.34%

$RARE